Clinical Trial Update: Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male Subjects [Phase 1]

View source ↗

Summary

Phase 1 bioequivalence study of rivaroxaban in healthy Japanese adult male subjects has completed. Sponsored by Bayer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Venous Thromboembolism

Drugs mentioned

• Xarelto (rivaroxaban)

Snippet

Sponsor: Bayer | Conditions: Embolism, Atrial Fibrillation and Venous Thrombosis | Phase 1 | Status: COMPLETED